Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis
This study confirms OCR's significant efficacy in reducing relapse rates and its manageable safety profile in MS. However, its benefits on composite endpoints like NEDA and on halting disability progression remain uncertain and variable, highlighting a need for long-term studies to better define its role in mitigating disease progression.
Authors
- Mahmoud M Taha (ORCID: https://orcid.org/0009-0003-9250-7959)
- Ejaz Ahmad Khan (ORCID: https://orcid.org/0009-0003-0085-0777)
- Muhammad Qasim (ORCID: https://orcid.org/0009-0009-1628-0370)
- Muhammad Abbas
- Asad Ullah Nawaz (ORCID: https://orcid.org/0009-0007-8996-2474)
- Muhammad Saad (ORCID: https://orcid.org/0009-0008-9510-7615)
- Arsalan Bakhtiyar (ORCID: https://orcid.org/0009-0007-0930-8000)
- Erum Siddiqui (ORCID: https://orcid.org/0009-0006-7183-1022)
- Muhammad Ibrahim Khan (ORCID: https://orcid.org/0009-0003-2326-6004)
Institutions
- Karachi Medical and Dental College (PK)
- Khyber Medical College (PK)
- Khyber Medical University (PK)
- Jinnah Sindh Medical University (PK)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12883-025-04519-4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00